|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer显示文摘 | Douglas K Rex John H Bond Sidney Winawer Theodore R Levin Randall W Burt David A Johnson Lynne M Kirk Scott Litlin David A Lieberman Jerome D Waye James Church John B Marshall Robert H Riddell | 2002 | The American Journal of Gastroenterology2002，，6： | 3 |
| 2 | Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals显示文摘AIM:To examine trends in and correlates of liver disease and viral hepatitis in an human immunodeficiency virus (HIV)-infected cohort. METHODS:The multi-site adult/adolescent spectrum of HIV-related diseases (ASD) followed 29 490 HIVinfected individuals receiving medical care in 11 U.S. metropolitan areas for an average of 2.4 years,and a total of 69 487 person-years,between 1998 and 2004. ASD collected data on the presentation,treatment,and outcomes of HIV,including liver disease,hepatitis screening,and hepatitis diagnoses. RESULTS:Incident liver disease,chronic hepatitis B virus (HBV),and hepatitis C virus (HCV) were diagnosed in 0.9,1.8,and 4.7 per 100 person-years. HBV and HCV screening increased from fewer than 20% to over 60% during this period of observation (P < 0.001). Deaths occurred in 57% of those diagnosed with liver disease relative to 15% overall (P < 0.001). Overall 10% of deaths occurred among individuals with a diagnosis of liver disease. Despite care guidelines promoting screening and vaccination for HBV and screening for HCV,screening and vaccination were not universally conducted or,if conducted,not documented. CONCLUSION:Due to high rates of incident liver disease,viral hepatitis screening,vaccination,and treatment among HIV-infected individuals should be a priority. | Susan E Buskin Elizabeth A Barash John D Scott David M Aboulafia Robert W Wood | 2011 | World Journal of Gastroenterology2011，17，14： | 2 |
| 3 | IL 28 B genotype is not useful for predicting treatment outcome in A sian chronic hepatitis B patients treated with pegylated interferon‐α显示文摘 | Jacinta A Holmes Tin Nguyen Dilip Ratnam Neel M Heerasing Jane V Tehan Sara Bonanzinga Anouk Dev Sally Bell Stephen Pianko Robert Chen Kumar Visvanathan Rachel Hammond David Iser Ferry Rusli William Sievert Paul V Desmond D Scott Bowden Alexander J Thomps | 2013 | J Gastroenterol Hepatol2013，，5： | 2 |
| 4 | Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection显示文摘 | Shi Guanfang Field David J Ko Kyung-ae Ture Sara Srivastava Kalyan Levy Scott Kowalska M Anna Poncz Mortimer Fowell Deborah J Morrell Craig N | 2014 | Journal of Clinical Investigation2014，，： | 1 |
| 5 | Framework for polarized radiance signature prediction for natural scenes显示文摘 | Chabitha D Scott B David M | 2007 | Proc of SHE2007，6565，65650： | 1 |
| 6 | Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the dialytic human retina and choroids显示文摘 | Scott M David J Carol M | 1995 | Am J Pathol1995，147，3： | 1 |
| 7 | Inhibitors of hepatitis C virus NS3·4A protease. Part 3: P 2 proline variants显示文摘 | Robert B Perni Luc J Farmer Kevin M Cottrell John J Court Lawrence F Courtney David D Deininger Cynthia A Gates Scott L Harbeson Joseph L Kim Chao Lin Kai Lin Yu-Ping Luong John P Maxwell Mark A Murcko Janos Pitlik B.Govinda Rao Wayne C Schairer Roger D T | 2004 | Bioorganic & Medicinal Chemistry Letters2004，，8： | 1 |
| 8 | Effects of decay on the cyclic properties of nailed connections 显示文摘 | Scott M K Robert J L David V R | 2005 | Journal of Materials in Civil Engineering2005，910，： | 1 |
| 9 | Non-traditional Resolutions to Mass Tort Dispute Take a Hit as AIDS-Infected Persons with Hemophilia Bear the Cost of Judge Posner' s' Economic Justice' 显示文摘 | David M Scott | 1996 | Ohio State Journal on Dispute Resolution1996，12，： | 1 |
| 10 | Bond Strength Development with Maturity of High-Early-Strength Bonded Concrete Overlays显示文摘 | M Scott Williamson David W Fowler | 2000 | ACI Materials Journal2000，97，2： | 1 |
| 11 | Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes显示文摘 | Scott B Halstead Suresh Mahalingam Mary A Marovich Sukathida Ubol David M Mosser | 2010 | The Lancet Infectious Diseases2010，，10： | 1 |
| 12 | Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma显示文摘 | Scott J Swanson Hasan F Batirel Raphael Bueno Michael T Jaklitsch Jeanne M Lukanich Elizabeth Allred Steven J Mentzer David J Sugarbaker | 2001 | The Annals of Thoracic Surgery2001，，6： | 1 |
| 13 | Short-term effects of exercise and music on cognitive performance among participants in a cardiac rehabilitation program显示文摘 | Charles F Emery Evana T Hsiao Scott M Hill David J Frid | 2003 | Heart & Lung - The Journal of Acute and Critical Care2003，，6： | 1 |
| 14 | Polyolefins with controlled environmental degradabillty显示文摘 | Gerald Scott | 2006 | Polymer Degradation and Stability2006，91，： | 1 |
| 15 | Programmed~life plastics from polyolefins:A new look at snstainability显示文摘 | David M Wiles | 2001 | Biomacromolecules2001，2，3： | 1 |
| 16 | PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial显示文摘 | Frederick J Raal Evan A Stein Robert Dufour Traci Turner Fernando Civeira Lesley Burgess Gisle Langslet Russell Scott Anders G Olsson David Sullivan G Kees Hovingh Bertrand Cariou Ioanna Gouni-Berthold Ransi Somaratne Ian Bridges Rob Scott Scott M Wasserm | 2015 | The Lancet . 2015 (9965)2015，，9965： | 1 |
| 17 | 建设恢复力和适应性以对付北极的变化显示文摘人类行为引起的空前的全球变化挑战着社会支撑我们这颗行星保持自身优点的能力。这就要求对变化进行主动的管理以培养地球的恢复力——维持在变化的情况下对社会很重要的一些属性,和适应性——发展新的社会生态构造以便在新的条件下有效地发挥作用。北极的广大地区仍然完整地保留着原型的生态及社会过程及反馈,这为我们为变化预先做出计划提供了可能是最后一个实验的机会。如果该策略的可行性在北极可以被证实,我们对于变化的动态所得到的进一步的理解就可以实施到那些被人类较大地改变了的地区中。现在执行管理北极变化的政策的条件可能很理想,因为近来的研究提供了极其重要的科学知识,合适的国际机制也已各就各位,而且,如果北极地区的国家选择这样做的话,他们具备实行必要改变的财力。 | F.Stuart Chapin Ⅲ Michael Hoel Steven R.Carpenter Jane Lubchenco Brian Walker Terry V.Callaghan Carl Folke Simon A.Levin Karl-Gran Mler Christer Nilsson Scott Barrett Fikret Berkes Anne-Sophie Crépin Kjell Danell Thomas Rosswall David Starrett Anastasios Xepapadeas Sergey A.Zimov 陈卓天 | 2006 | AMBIO-人类环境杂志2006，35，4： | 1 |
| 18 | Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroids显示文摘 | David J Carol M | 1995 | Am J Pathol1995，147，： | 1 |
| 19 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 20 | Widespread expression of Huntington’s disease gene (IT15) protein product显示文摘 | Alan H Sharp Scott J Loev Gabriele Schilling Shi-Hua Li Xiao-Jiang Li Jun Bao Molly V Wagster Joyce A Kotzuk Joseph P Steiner Amy Lo John Hedreen Sangram Sisodia Solomon H Snyder Ted M Dawson David K Ryugo Christopher A Ross | 1995 | Neuron1995，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员